Trial Profile
An Open Label, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab (MK-3475) Before Cystectomy for Patients With Muscle-invasive Urothelial Bladder Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2024
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms PURE-01
- 27 Jan 2024 Results assessing the shifting spectrum of genomic alterations (GA) in matched pre-post therapy samples could orient novel therapeutic sequences from patients with cT2-4N0M0 MIBC who received neoadjuvant pembrolizumab in the PURE-01 (n=129) study, or standard cisplatin-based neoadjuvant chemotherapy (NACT), preceding RC center (n=27; from 2017 to 2022), presented at the 2024 Genitourinary Cancers Symposium.
- 06 Oct 2023 Results (n=110) assessing the predictive capability of the pre- and post-pembrolizumab vesical imaging-reporting and data system (VI-RADS) to identify ypT0N0 or ypT less than equal to 1N0 response in muscle-invasive bladder cancer (MIBC) within the PURE-01 trial, published in the BJU International.
- 14 Jul 2023 Status changed from recruiting to completed.